Cargando…
Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
BACKGROUND: In this work, we have identified heterocyclic derivatives with 1,2,4 oxadiazole scaffold mimicking the functions of tyrosine kinase inhibitors. Fourteen molecules that displayed the best fit were picked from the library of compounds and studied under in-silico and in-vitro conditions. Fo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077134/ https://www.ncbi.nlm.nih.gov/pubmed/35535170 http://dx.doi.org/10.2147/OTT.S357765 |
_version_ | 1784702071394533376 |
---|---|
author | Unadkat, Vishal Rohit, Shishir Parikh, Paranjay Patel, Kaushal Sanna, Vinod Singh, Sanjay |
author_facet | Unadkat, Vishal Rohit, Shishir Parikh, Paranjay Patel, Kaushal Sanna, Vinod Singh, Sanjay |
author_sort | Unadkat, Vishal |
collection | PubMed |
description | BACKGROUND: In this work, we have identified heterocyclic derivatives with 1,2,4 oxadiazole scaffold mimicking the functions of tyrosine kinase inhibitors. Fourteen molecules that displayed the best fit were picked from the library of compounds and studied under in-silico and in-vitro conditions. Four compounds were selected for further cytotoxicity and ADME (Absorption, Distribution, Metabolism, Elimination) profiling showing IC(50) (from 8–13 µM) values against EGFR positive cancer cell line (MCF7). METHODS: A molecular dynamics simulation study was performed to understand the correlation of non-covalent binding energies with biological activity. The drug-like properties of the selected four compounds (7a, 7b, 7e, and 7m) were evaluated by in-vitro ADME studies. Compounds 7a, 7b, and 7m were the active compounds in the molecular dynamics simulations study. Further, EGFR binding activity was confirmed with EGFR(WT) and EGFR(T790M) kinase assay using a luminescence-based method. RESULTS: These compounds (7a, 7b, and 7m) showed activity against EGFR(WT) and mutant EGFR(T790M), exhibiting IC(50) values of <10 and <50 micromolar, respectively. These compounds also possess moderate aqueous solubility in 40–70 µg/mL at pH 7.4 and 30–100 µg/mL at pH 4.0. Further, 7a, 7b, and 7m showed balanced lipophilicity with Log D values ranging from 1–3. They demonstrated a good correlation in Caco-2 permeability with Apparent permeability (Papp) 1 to 5 × 10(−6) cm/s in comparison with 7e, which was found to be highly lipophilic (Log D >5) and showed high permeability (Papp 17 × 10(−6) cm/s). Lastly, all these compounds were moderately stable in liver microsomes at alkaline pH with a half-life of 30–60 min, while at a highly acidic pH (2.0), the compounds were stable up to 15–20 min. CONCLUSION: Overall, in-vitro ADME results of these molecules showed good drug-like properties, which are well correlated with the in-silico ADME data, making them ideal for developing an oral drug delivery formulation. |
format | Online Article Text |
id | pubmed-9077134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90771342022-05-08 Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies Unadkat, Vishal Rohit, Shishir Parikh, Paranjay Patel, Kaushal Sanna, Vinod Singh, Sanjay Onco Targets Ther Original Research BACKGROUND: In this work, we have identified heterocyclic derivatives with 1,2,4 oxadiazole scaffold mimicking the functions of tyrosine kinase inhibitors. Fourteen molecules that displayed the best fit were picked from the library of compounds and studied under in-silico and in-vitro conditions. Four compounds were selected for further cytotoxicity and ADME (Absorption, Distribution, Metabolism, Elimination) profiling showing IC(50) (from 8–13 µM) values against EGFR positive cancer cell line (MCF7). METHODS: A molecular dynamics simulation study was performed to understand the correlation of non-covalent binding energies with biological activity. The drug-like properties of the selected four compounds (7a, 7b, 7e, and 7m) were evaluated by in-vitro ADME studies. Compounds 7a, 7b, and 7m were the active compounds in the molecular dynamics simulations study. Further, EGFR binding activity was confirmed with EGFR(WT) and EGFR(T790M) kinase assay using a luminescence-based method. RESULTS: These compounds (7a, 7b, and 7m) showed activity against EGFR(WT) and mutant EGFR(T790M), exhibiting IC(50) values of <10 and <50 micromolar, respectively. These compounds also possess moderate aqueous solubility in 40–70 µg/mL at pH 7.4 and 30–100 µg/mL at pH 4.0. Further, 7a, 7b, and 7m showed balanced lipophilicity with Log D values ranging from 1–3. They demonstrated a good correlation in Caco-2 permeability with Apparent permeability (Papp) 1 to 5 × 10(−6) cm/s in comparison with 7e, which was found to be highly lipophilic (Log D >5) and showed high permeability (Papp 17 × 10(−6) cm/s). Lastly, all these compounds were moderately stable in liver microsomes at alkaline pH with a half-life of 30–60 min, while at a highly acidic pH (2.0), the compounds were stable up to 15–20 min. CONCLUSION: Overall, in-vitro ADME results of these molecules showed good drug-like properties, which are well correlated with the in-silico ADME data, making them ideal for developing an oral drug delivery formulation. Dove 2022-05-02 /pmc/articles/PMC9077134/ /pubmed/35535170 http://dx.doi.org/10.2147/OTT.S357765 Text en © 2022 Unadkat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Unadkat, Vishal Rohit, Shishir Parikh, Paranjay Patel, Kaushal Sanna, Vinod Singh, Sanjay Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies |
title | Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies |
title_full | Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies |
title_fullStr | Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies |
title_full_unstemmed | Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies |
title_short | Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies |
title_sort | identification of 1,2,4-oxadiazoles-based novel egfr inhibitors: molecular dynamics simulation-guided identification and in vitro adme studies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077134/ https://www.ncbi.nlm.nih.gov/pubmed/35535170 http://dx.doi.org/10.2147/OTT.S357765 |
work_keys_str_mv | AT unadkatvishal identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies AT rohitshishir identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies AT parikhparanjay identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies AT patelkaushal identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies AT sannavinod identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies AT singhsanjay identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies |